# Selective cholecystokinin receptor signaling in the pancreatic islet as therapeutic target against diabetogenic stress

> **NIH NIH F31** · UNIVERSITY OF WISCONSIN-MADISON · 2021 · $30,444

## Abstract

Project Summary:
Epidemiological studies show that during the past three decades, there has been an alarming rate of growth in
the number of type 2 diabetes patients, consequently driving the myriad diabetes-related complications and
related mortality. The annual excess financial cost to society from 30 million diabetes patients and 86 million
prediabetes patients is estimated to be $322 billion, a whopping 20% of the total health care spending in
America with much more regarding lost revenue and associated immeasurable human suffering. Type 2
diabetes mellitus results from both increased insulin resistance and decreased insulin production. There is a
failure of adaptive pancreatic β-cell proliferation under diabetic stress, as well as increased apoptosis leading
to β-cell mass reduction. Cholecystokinin (CCK) is an incretin-like hormone produced by pancreatic β-cells
under conditions of stress and obesity. Obese mouse islets lacking CCK have decreased β-cell mass and
increased apoptosis. In pancreatic endocrine cells, we have demonstrated that CCK is both necessary and
sufficient to promote β-cell survival and to protect from cytokine-mediated β-cell death. However, despite the
accumulated observations of a pro-survival effect of CCK in various cell types and disease models, CCK
receptor expression and activation in the β-cell is mostly unknown. There is a need to understand which CCK
receptor mediates the pro-survival effects in the -cell to develop a therapeutic that will take advantage of the
positive effects of CCK in the -cell with a minimal amount of off-target side effects in other tissues. The long-
term goal of this proposal is to identify and distinguish the functions of the CCK signaling pathways,
understand how they contribute to the β-cell protective effect in the pancreatic islet under diabetic stress, and
determine the therapeutic significance of specific CCKR agonism. To that end, this proposal is aimed to test
the central hypothesis that selective modulation of CCK receptor subtype-specific signaling in a beta-cell can
protect β-cell function and mass. With the completion of this project, we anticipate to better understand the
therapeutic potential of selective CCK agonist which will open new avenues of developing a better tolerated,
target specific, and clinically relevant drug by identifying direct roles and mechanisms by which CCK signaling
promotes β-cell survival. Finally, the completion of this project will ensure the successful progression of both
research and professional career development towards the end of my doctoral training in molecular and
cellular pharmacology, allowing a balanced development of qualities and experiences needed for a graduate
student to make a smooth transition into the next stage of career in science where I will continue to progress
towards becoming a successful, tenured professor in the field of islet biology.

## Key facts

- **NIH application ID:** 10112232
- **Project number:** 5F31DK120275-03
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **Principal Investigator:** HyungTae Kim
- **Activity code:** F31 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $30,444
- **Award type:** 5
- **Project period:** 2019-03-01 → 2021-08-22

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10112232

## Citation

> US National Institutes of Health, RePORTER application 10112232, Selective cholecystokinin receptor signaling in the pancreatic islet as therapeutic target against diabetogenic stress (5F31DK120275-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10112232. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*